Clinical Trial: Endotype DIrected Treatment for OSA in Down Syndrome

U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07280468) titled 'Endotype DIrected Treatment for OSA in Down Syndrome' on Nov. 23.

Brief Summary: Down syndrome is the most common genetic cause of intellectual disability. People with Down syndrome often have obstructive sleep apnea (OSA), a condition where people have difficulties with breathing while asleep. OSA can lead to poor sleep, worse quality of life, behavior problems and more difficulties with thinking ("cognitive impairment"). Current treatments for OSA in people with Down syndrome are not very effective or require surgery. The combination of 2 medications, atomoxetine and oxybutynin ("ato-oxy") is a promising treatment for OSA in peopl...